Fennec Pharmaceuticals CCO Shubh Goel resigns; effective late February

FENNEC PHARMACEUTICALS INC.

Shubh Goel, chief commercial officer, tendered resignation on Jan 31, 2022.
Goel will depart in late February 2022.
CEO Rosty Raykov thanked Goel for contributions; company continues launch preparations for PEDMARK.
PEDMARK is a treatment for cisplatin-induced ototoxicity in pediatric patients, pending approval.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Shubh Goel

Chief Commercial Officer

FENC · FENNEC PHARMACEUTICALS INC.

Filed: January 31, 2022, 6:59 PM ET

On January 31, 2022 Fennec Pharmaceuticals Inc. announced the resignation of Chief Commercial Officer, Shubh Goel.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Shubh Goel resigned as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On January 31, 2022 Fennec Pharmaceuticals Inc. announced the resignation of Chief Commercial Officer, Shubh Goel.

View on SEC.gov

FENNEC PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-009272

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.